Commercialization of medical sensors is the pathway to democratize healthcare by reducing the cost of diagnosis and enabling continuous monitoring for at risk groups to catch disease before it becomes chronic and extremely challenging and invasive to treat. Often when disease or injury is discovered in the early stages, it can be treated with minimal medical intervention, diet, exercise and physical therapy. For innovative medical sensors to reach the market and be available to the masses, design for commercialization is essential. This will cause significant disruption in healthcare by improving access, equity and outcomes. This webinar will examine two medical sensors in development or early stages of commercialization and evaluate their commercialization readiness. Factors to be considered in this evaluation include the need, overall impact, time to market, FDA approval, continuous vs intermittent monitoring, design for manufacture and quality, software integration, performance, cost and use of a core technology building block for future derivatives and business growth.
The first medical sensor to be evaluated for commercial readiness is a remote temperature monitoring system that monitors temperature differences between multiple locations on the same foot and between feet to detect
a future diabetic foot ulcer before it occurs. The system then sends actionable information via a smart device to patients and doctors. The second medical sensor to be evaluated for commercial readiness is the first non-invasive, saliva-based glucose test for diabetes management. The Saliva Glucose Biosensor makes contact with saliva, senses the glucose levels and this information is transferred to a smart device for analysis and interpretation. Click here for the slides.